# Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis

> **NCT03883360** · PHASE2 · WITHDRAWN · sponsor: **University of Maryland, Baltimore**

## Conditions studied

- Schizophrenia Spectrum Disorders
- Cannabis Use

## Interventions

- **DRUG:** Cannabidiol (CBD)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03883360
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2050-01
- **Primary completion:** 2050-02
- **Final completion:** 2050-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** not funded
- **Last updated:** 2021-04-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03883360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03883360, "Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT03883360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*